Bio Rad Laboratories IncNYSE:BIO
- LAST PRICE288.9600
- TODAY'S CHANGE (%)2.1000 (0.7321%)
- Bid / Lots265.8000/ 1
- Ask / Lots296.1800/ 1
- Open / Previous Close286.9600 / 286.8600
- Day Range
- 52 Week Range
- Volume233,221
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIO |
|---|---|---|
| 09:32 ET | 2443 | 286.96 |
| 09:36 ET | 1273 | 288.7 |
| 09:38 ET | 100 | 288.76 |
| 09:41 ET | 213 | 289.65 |
| 09:43 ET | 499 | 289.25 |
| 09:45 ET | 200 | 289.83 |
| 09:48 ET | 3748 | 289.78 |
| 09:52 ET | 400 | 291.96 |
| 09:56 ET | 200 | 291.3 |
| 09:57 ET | 1834 | 291.59 |
| 09:59 ET | 100 | 291.76 |
| 10:01 ET | 100 | 292.04 |
| 10:08 ET | 328 | 292.51 |
| 10:14 ET | 100 | 291.73 |
| 10:15 ET | 100 | 291.75 |
| 10:19 ET | 300 | 289.98 |
| 10:21 ET | 100 | 289.79 |
| 11:40 ET | 100 | 287.65 |
| 11:42 ET | 100 | 288.28 |
| 11:44 ET | 800 | 287.58 |
| 11:45 ET | 100 | 287.78 |
| 11:47 ET | 100 | 287.575 |
| 11:49 ET | 100 | 288.07 |
| 11:51 ET | 200 | 287.595 |
| 11:58 ET | 100 | 287.542 |
| 12:00 ET | 100 | 287.79 |
| 12:02 ET | 100 | 288.08 |
| 12:03 ET | 100 | 288.15 |
| 12:12 ET | 503 | 288.655 |
| 12:14 ET | 600 | 288.82 |
| 12:16 ET | 448 | 288.87 |
| 12:21 ET | 100 | 288.93 |
| 12:23 ET | 272 | 288.755 |
| 12:25 ET | 400 | 288.16 |
| 12:27 ET | 100 | 288.24 |
| 12:30 ET | 200 | 288.22 |
| 12:34 ET | 300 | 287 |
| 12:36 ET | 100 | 286.84 |
| 12:38 ET | 873 | 286.7 |
| 12:41 ET | 100 | 286.24 |
| 12:43 ET | 373 | 286.7 |
| 12:45 ET | 100 | 286.72 |
| 12:52 ET | 123 | 286.215 |
| 12:56 ET | 505 | 286.74 |
| 12:57 ET | 200 | 286.93 |
| 12:59 ET | 100 | 286.595 |
| 01:03 ET | 200 | 286.175 |
| 01:06 ET | 200 | 285.47 |
| 01:12 ET | 677 | 285.3 |
| 01:14 ET | 759 | 285.44 |
| 01:15 ET | 200 | 286.55 |
| 01:17 ET | 1890 | 288.2 |
| 01:26 ET | 200 | 288.1 |
| 01:28 ET | 479 | 288.36 |
| 01:30 ET | 100 | 288.01 |
| 01:32 ET | 100 | 287.995 |
| 01:33 ET | 100 | 287.98 |
| 01:35 ET | 200 | 287.575 |
| 01:37 ET | 100 | 287.69 |
| 01:42 ET | 300 | 288.095 |
| 01:46 ET | 936 | 288.41 |
| 01:48 ET | 100 | 288.566 |
| 01:50 ET | 403 | 288.84 |
| 01:51 ET | 600 | 288.715 |
| 01:53 ET | 871 | 289.08 |
| 01:55 ET | 200 | 288.96 |
| 01:57 ET | 100 | 289.095 |
| 02:00 ET | 100 | 289.09 |
| 02:02 ET | 100 | 289.09 |
| 02:11 ET | 100 | 289.31 |
| 02:15 ET | 200 | 289.21 |
| 02:20 ET | 200 | 289.32 |
| 02:22 ET | 418 | 289.44 |
| 02:24 ET | 100 | 289.14 |
| 02:26 ET | 200 | 289.09 |
| 02:33 ET | 100 | 289.42 |
| 02:42 ET | 100 | 289.75 |
| 02:44 ET | 100 | 289.79 |
| 02:45 ET | 100 | 289.55 |
| 02:47 ET | 100 | 289.24 |
| 02:49 ET | 300 | 289.23 |
| 02:51 ET | 300 | 288.855 |
| 02:54 ET | 193 | 288.925 |
| 02:56 ET | 200 | 289.06 |
| 02:58 ET | 200 | 289.18 |
| 03:00 ET | 200 | 289.41 |
| 03:02 ET | 100 | 289.7 |
| 03:05 ET | 331 | 289.55 |
| 03:09 ET | 400 | 289.58 |
| 03:12 ET | 100 | 289.47 |
| 03:14 ET | 100 | 289.465 |
| 03:16 ET | 100 | 289.44 |
| 03:20 ET | 200 | 289.2 |
| 03:21 ET | 100 | 289.31 |
| 03:23 ET | 100 | 289.21 |
| 03:25 ET | 300 | 289.115 |
| 03:27 ET | 200 | 289.26 |
| 03:32 ET | 300 | 288.73 |
| 03:34 ET | 670 | 288.95 |
| 03:36 ET | 100 | 289 |
| 03:38 ET | 498 | 288.68 |
| 03:39 ET | 731 | 288.63 |
| 03:45 ET | 100 | 287.99 |
| 03:48 ET | 138 | 287.4313 |
| 03:50 ET | 1197 | 288.255 |
| 03:52 ET | 442 | 288.809 |
| 03:54 ET | 1271 | 288.76 |
| 03:56 ET | 500 | 288.28 |
| 03:57 ET | 1531 | 288.5 |
| 03:59 ET | 1506 | 288.96 |
Today
May 30, 2024
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group, from 9:00AM ET on Thursday May 30, 2024 by Dow Jones
9:00AM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference, from 4:15PM ET on Thursday May 23, 2024 by Dow Jones
4:15PM ET on Thursday May 23, 2024 by Dow Jones
May 8, 2024
DJ Bio-Rad Laboratories Is Maintained at Buy by UBS, from 9:37AM ET on Wednesday May 08, 2024 by Dow Jones
9:37AM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
Bio-Rad Reports First-Quarter 2024 Financial Results, from 4:15PM ET on Tuesday May 07, 2024 by Dow Jones
4:15PM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bio Rad Laboratories Inc | 8.1B | -27.9x | --- |
Teleflex Inc | 9.8B | 34.4x | +12.49% |
Globus Medical Inc | 9.1B | 105.5x | -7.04% |
Masimo Corp | 6.6B | 87.6x | -15.37% |
Repligen Corp | 8.3B | 595.6x | +15.08% |
Penumbra Inc | 7.3B | 79.1x | +65.82% |
Company Information
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Contact Information
- Headquarters
- 1000 ALFRED NOBEL DRHERCULES, CA, United States 94547-1811
- Phone
- 510-724-7000
- Fax
- 510-741-5817
Executives
- Chairman of the Board, President, Chief Executive Officer
- Norman Schwartz
- Chief Financial Officer, Executive Vice President, Principal Financial officer
- Roop Lakkaraju
- Chief Operating Officer, Executive Vice President
- Andrew Last
- Executive Vice President Global Human Resources
- Colleen Corey
- Executive Vice President, President - Life Science Group
- James Barry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.1B |
|---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 28.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-10.36 |
Book Value | $306.51 |
P/E Ratio | -27.9x |
Price/Sales (TTM) | 3.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 12.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
